Navigation Links
China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results
Date:5/18/2009

3 542,545 Comprehensive income $ 4,248,125 $ 3,667,526 $ 1,336,356 $ 976,112 Basic and Diluted Income per common share Basic $ 0.15 $ 0.09 $ 0.04 $ 0.01 Diluted $ 0.15 $ 0.09 $ 0.04 $ 0.01 Weighted average common share outstanding Basic 30,000,000 30,000,000 30,000,000 30,000,000 Diluted 30,000,000 30,000,000 30,000,000 30,000,000

CHINA DASHENG BIOTECHNOLOGY COMPANY (FORMERLY NAMED AS MAX NUTRITION INC.)

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) FOR THE NINE MONTHS ENDED

                   MARCH 31, 2009 AND 2008 (in US DOLLARS)

                                          For the nine months ended March 31,
                                                  2009              2008

    Cash Flows From Operating Activities:
       Net income                        $      4,364,589   $     2,596,845
       Adjustments to reconcile net
       income to net cash provided by
       operating activities:
                   Minority interest
                    in net income of
                    consolidated
                    subsidiaries                  973,579           607,097
                   Bad debt expense                 6,424                --
                   Depreciation expense           236,961           236,690
                   Amortization expense           170,027           110,544
                   Loss on disposal of
                    fixed asset                     4,922                --

    Changes in operating assets and
     liabilities:
                   Accounts receivable           (420,370)         (512,552)
                   Inventory                      (83,626)          196,945
                   Advance to suppliers         1,471,038                --
            
'/>"/>
SOURCE China Dasheng Biotechnology Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... , May 30, 2015 CTI BioPharma Corp. ... Bioscience business (NYSE: BAX ) today announced data ... examining pacritinib for the treatment of myelofibrosis – in ... Meeting of the American Society of Clinical Oncology (ASCO), ... Pacritinib is an investigational oral multikinase inhibitor ...
(Date:5/29/2015)... In recent years, the biopharmaceutical industry has ... that can generate valuable insights. Despite this, the inherent ... have caused the biopharmaceutical sector to embrace Big Data ... According to a recent study by benchmarking firm, Best ... Data team or function in place; however, these organizations ...
(Date:5/29/2015)... May 29, 2015 Asthma ... p ersonalized   treatments enter arena, says   ... Despite generic erosion facing several of the leading asthma ... fumarate) and Xolair (omalizumab), the global market for asthma ... end of the decade.   New analysis ...
(Date:5/29/2015)...  Caris Life Sciences® today announced the presentation ... utilized Caris Molecular Intelligence®, the company,s panomic, comprehensive ... in patients with colorectal and pancreatic cancer subtypes, ... protein 1 (PD-1) and its ligand, PD-L1. The ... American Society of Clinical Oncology Annual Meeting (ASCO) ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4
... Novagali Pharma, a French,pharmaceutical ophthalmic company, announces ... (IND) to conduct a Phase III clinical,trial ... glaucoma has been,granted by the U.S. Food ... ocular proprietary BAK-free formulation of latanoprost which,furthermore ...
... Milestone Payment from GlaxoSmithKlineMOUNTAIN VIEW, Calif., May 5 ... identified an orally bioavailable small molecule antagonist of ... clinical development. The acceptance of the molecule ... milestone payment from the alliance with GlaxoSmithKline (NYSE: ...
... May 5 Amylin Pharmaceuticals, Inc., (Nasdaq: ... LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) ... once weekly has been submitted to the U.S. Food and ... release medication for type 2 diabetes that is injected subcutaneously ...
Cached Biology Technology:Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With Glaucoma 2ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 2ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 3ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 4Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 2Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 3Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 4Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 5Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 6Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 7
(Date:5/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... owned subsidiary, 3D-ID LLC, a company engaged in biometric ... the biometrics technology portion of the recently awarded TIES ... Department of the Army. 3D-ID LLC has ... government, law enforcement and security agencies. ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/10/2015)... May 11, 2015 Fingerprint Cards (FPC) ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... used by smartphone manufacturers in China . ... communicated revenue guidance of + 1 000 MSEK for 2015.   ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... 95 percent genomic similarity to humans, mice have long been ... Once researchers can shine a light on the genetic factors ... prevention and treatment options to protect the human population. ... difficult road, made more challenging by the 5% difference between ...
... shown that a dramatic sea-level rise occurred at the onset ... as the Blling warming, approximately 14,600 years ago. This event, ... rapid collapse of massive ice sheets 14,600 years ago and ... are published in the 29 March 2012 issue of the ...
... The Cardiovascular Cell Therapy Research Network (CCTRN), a ... Health,s (NIH) National Heart, Lung and Blood Institute (NHLBI) ... of its seven U.S. centers of excellence. The network ... over the next seven years to help achieve its ...
Cached Biology News:New lab mice cut search for genetic links to disease by more than a decade 2New lab mice cut search for genetic links to disease by more than a decade 3Ice sheet collapse and sea-level rise at the Boelling warming 14,600 years ago 2Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network 2